PharmAthene wins ruling in fight over $78M anthrax contract

PharmAthene announced that it won a brawl with rival Emergent BioSolutions, obtaining a ruling from the Government Accountability Office that allows the developer to keep a $78 million contract to develop a second-generation anthrax vaccine. Emergent had claimed that PharmAthene had landed the contract in a sole source deal that should have been opened to bidders. Emergent makes BioThrax, the currently available anthrax vaccine, and sells it to government agencies. "While development activities...